VENCLEXTA Sample Coding
This coding information may assist you as you complete the payer forms for VENCLEXTA. These tables are provided for informational purposes only. Please visit CMS.gov or other payers’ websites to obtain additional guidance on their processes related to billing and coding for single-use vials and wastage.
Chronic Lymphocytic Leukemia
|Diagnosis: ICD-10-CM||C91.10||Chronic lymphocytic leukemia of B-cell
type not having achieved remission |
|C91.12||Chronic lymphocytic leukemia of B-cell type in relapse|
|Drug: NDC |
Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.
|0074-0579-28||00074-0579-28||Starting pack (contains 4 weekly wallet blister packs)|
|0074-0561-14||00074-0561-14||10 mg wallet (14 x 10 mg tablets)|
|0074-0566-07||00074-0566-07||50 mg wallet (7 x 50 mg tablets)|
|0074-0576-22||00074-0576-22||100 mg bottle (120 x 100 mg tablets)|
|0074-0561-11||00074-0561-11||10 mg unit dose (2 x 10 mg tablets)|
|0074-0566-11||00074-0566-11||50 mg unit dose (1 x 50 mg tablet)|
|0074-0576-11||00074-0576-11||100 mg unit dose (1 x 100 mg tablet)|
ICD-10-CM=International Classification of
Diseases, 10th Revision, Clinical Modification.
NDC=National Drug Code.
These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. VENCLEXTA Access Solutions does not make any representation or guarantee concerning reimbursement or coverage for any service or item.
Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.
If your patient’s health insurance plan has issued a denial, your BioOncology Field Reimbursement Manager (BFRM) or VENCLEXTA Access Solutions Specialist can provide resources as you prepare an appeal submission, as per your patient’s plan requirements.
If a plan issues a denial:
- The denial should be reviewed, along with the health insurance
plan’s guidelines to determine what to include in your patient’s
- Your BFRM or Genentech
BioOncology® Access Solutions Specialist has local payer coverage
expertise and can help you determine specific requirements for your
A sample appeal letter, checklist and additional tips are available in Forms and Documents.
Appeals cannot be completed or submitted by VENCLEXTA Access Solutions on your behalf.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.